Table 3. Associations of SEP-1 and Components With Risk of Mortality and Vasopressor Days in Rebalanced Cohorts With Community-Onset and Hospital-Onset Sepsis.
| Component | Sepsisa | |
|---|---|---|
| Community-onset | Hospital-onset | |
| Risk of mortality difference, percentage points (95% CI) | ||
| SEP-1 bundle | −0.07 (−3.02 to 2.88) | −0.42 (−6.77 to 5.93) |
| Blood cultures | −6.37 (−15.70 to 2.96) | −2.30 (−8.33 to 3.74) |
| Serum lactate level testing | −7.61 (−14.70 to −0.54)b | −1.43 (−6.30 to 3.43) |
| Broad-spectrum intravenous antibiotic treatment | −3.50 (−8.58 to 1.59) | −5.20 (−9.84 to −0.56)b |
| Intravenous fluid treatment | −0.35 (−7.29 to 6.59) | −6.10 (−17.20 to 4.96) |
| Vasopressor days, mean absolute difference (95% CI) | ||
| SEP-1 bundle | 0.31 (0.11 to 0.51)b | 0.40 (−0.04 to 0.85) |
| Blood cultures | −1.10 (−1.85 to −0.34) | −0.07 (−0.52 to 0.38) |
| Serum lactate level testing | −0.49 (−1.01 to 0.04) | 0.26 (−0.15 to 0.67) |
| Broad-spectrum intravenous antibiotic treatment | −0.62 (−1.02 to −0.22)b | −0.02 (−0.35 to 0.32) |
| Intravenous fluid treatment | −0.57 (−1.19 to 0.05) | 0.33 (−0.45 to 1.11) |
Abbreviation: SEP-1, Early Management Bundle for Severe Sepsis/Septic Shock.
a
Outcomes are reported as the differences between treated and untreated. Risk of mortality difference is expressed in terms of percentage points.
b
Statistical significance defined as 2-sided P < .05.